Get the Stockscreener App
55.41
0.47%
-0.26
Pre-market:
60.40
4.99
+9.01%
Scholar Rock Holding Corp stock is traded at $55.41, with a volume of 921.67K.
It is down -0.47% in the last 24 hours and up +6.41% over the past month.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
See More
Previous Close:
$55.67
Open:
$55.67
24h Volume:
921.67K
Relative Volume:
0.71
Market Cap:
$6.75B
Revenue:
$47.30M
Net Income/Loss:
$-408.73M
P/E Ratio:
-15.45
EPS:
-3.5865
Net Cash Flow:
$-303.86M
1W Performance:
+0.14%
1M Performance:
+6.41%
6M Performance:
+28.32%
1Y Performance:
+74.03%
1-Day Range:
$54.91
$56.94
1-Week Range:
$53.86
$57.79
52-Week Range:
$27.07
$61.76
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
55.41 | 6.75B | 47.30M | -408.73M | -303.86M | -3.5865 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-21-26 | Initiated | Canaccord Genuity | Buy |
| Jan-09-26 | Initiated | Citigroup | Buy |
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
SRRK Shares Surge 12% After FDA Approval of Isembyld for Spinal Muscular Atrophy - GuruFocus
SRRK Stock Gains After Company Drops Troubled Novo Nordisk-Owned Plant From FDA Filing - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Second Time’s The Charm: FDA Clears Scholar Rock’s SMA Drug Ahead Of Deadline, SRRK Soars 15% After-Hours - Stocktwits
Scholar Rock (SRRK) Gains FDA Approval for Isembyld Amid High Pr - GuruFocus
FDA Approves Isembyld (apitegromab-mstn), the First and Only Muscle-Targeted Therapy for Spinal Muscular Atrophy, Marking a New Milestone in SMA Treatment - GlobeNewswire Inc.
Scholar Rock at citigroup biopharma summit: FDA decision nears By Investing.com - Investing.com Nigeria
BMO reiterates Scholar Rock stock Outperform on SMA drug uptake - Investing.com
BMO reiterates Scholar Rock stock Outperform on SMA drug uptake By Investing.com - Investing.com India
Scholar Rock at citigroup biopharma summit: FDA decision nears - Investing.com
Scholar Rock Holding Corporation $SRRK Stock Position Lifted by Squarepoint Ops LLC - MarketBeat
Scholar Rock at cantor global healthcare conference: approval clock nears By Investing.com - Investing.com South Africa
SRRK Reiterates by HC Wainwright & Co. -- Price Target Maintained at $65 - GuruFocus
Scholar Rock's (SRRK) Buy Rating Reaffirmed at HC Wainwright - MarketBeat
Legal & General Group Plc Invests $3.36 Million in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock (SRRK) Gains FDA Fast Track for Apitegromab Amid Hi - GuruFocus
122,223 Shares in Scholar Rock Holding Corporation $SRRK Acquired by The Manufacturers Life Insurance Company - marketbeat.com
Beaconlight Capital LLC Makes New Investment in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding (SRRK) Stock Dropped, So What Is Behind The Latest Attention? - simplywall.st
Bank of New York Mellon Corp Acquires New Shares in Scholar Rock Holding Corporation $SRRK - MarketBeat
104,346 Shares in Scholar Rock Holding Corporation $SRRK Acquired by Man Group plc - MarketBeat
Algert Global LLC Grows Stock Holdings in Scholar Rock Holding Corporation $SRRK - MarketBeat
Jupiter Topco LLC Invests $123.28 Million in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock (NASDAQ:SRRK) Shares Up 5.8%Still a Buy? - MarketBeat
Nicholas Investment Partners LP Purchases New Position in Scholar Rock Holding Corporation $SRRK - MarketBeat
9,494,084 Shares in Scholar Rock Holding Corporation $SRRK Purchased by BlackRock Inc. - marketbeat.com
Scholar Rock Holding Corp stock hits 52-week high at 58.52 USD - Investing.com Canada
Scholar Rock (SRRK) Is Up 8.5% After De-Risking Apitegromab’s Global Filing PathwayHas The Bull Case Changed? - sahmcapital.com
Scholar Rock (SRRK) Stock Trades At A Premium As Its 8x Run Continues - simplywall.st
Scholar Rock (SRRK) Streamlines Apitegromab Filings After Catalent Shift Is Regulatory Strategy De-Risking The Story? - Yahoo Finance
Scholar Rock withdraws Europe filing for muscle weakness drug, plans resubmission - Reuters
Scholar Rock (NASDAQ:SRRK): Healthcare Milestone Draws Focus - Kalkine Media
Scholar Rock advances apitegromab FDA review - grafa.com
Scholar Rock removes Catalent facility from SMA drug application By Investing.com - Investing.com Canada
Scholar Rock is prepared to launch its SMA drug if FDA approves by Sept. 30 - Stock Titan
Eagle Health Investments LP Invests $30.54 Million in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Scholar Rock Holding (SRRK) After Apitegromab Progress Is The Stock Already Fully Valued - Sahm
Scholar Rock Eyes Sept. 30 FDA Decision for SMA Drug Apitegromab - MarketBeat
How Investors Are Reacting To Scholar Rock (SRRK) Dual Fill-Finish Readiness Amid Ongoing FDA Review - simplywall.st
Is Scholar Rock Holding Corporation (SRRK) Better Positioned than Novo Nordisk A/S (NVO) After Recent Setbacks? - Yahoo Finance
Redmile Group (SRRK) updates Scholar Rock stake to 3.6% of common stock - Stock Titan
12 New Hires Receive 51,947 Scholar Rock Equity Awards - Stock Titan
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
SRRK Stock Surges To Near Five-Year Highs – Here’s Why Analysts Are Bullish About Its Latest FDA Filing - Stocktwits
Scholar Rock (SRRK) Stock Looks Priced At A Premium Today - simplywall.st
SRRK Maintains by JP Morgan -- Price Target Raised to $63.00 - GuruFocus
Scholar Rock (NASDAQ:SRRK) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Invus reports 8.0% stake in Scholar Rock (SRRK) through 9.6M shares - Stock Titan
SRRK Stock Prediction: Huge SMA Drug Launch Breakthrough? (2026 Alert) The Rock (yAPbDwyblt) - Mshale
Scholar Rock at canaccord growth conference: approval path narrows By Investing.com - Investing.com Canada
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
1.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):